Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-EARLY acoramidis prevention study in asymptomatic TTR variant carriers
NL-OMON59967Phase 3Recruiting
- Sponsor
- Eidos Therapeutics
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR) comparing Acoramidis with Placebo (2 arms). Primary endpoint: Time to development of ATTR. Started Apr 2025; status: recruiting.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NL-OMON59967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59967.